JP7425066B2 - 核酸を臓器特異的送達するための組成物および方法 - Google Patents
核酸を臓器特異的送達するための組成物および方法 Download PDFInfo
- Publication number
- JP7425066B2 JP7425066B2 JP2021536681A JP2021536681A JP7425066B2 JP 7425066 B2 JP7425066 B2 JP 7425066B2 JP 2021536681 A JP2021536681 A JP 2021536681A JP 2021536681 A JP2021536681 A JP 2021536681A JP 7425066 B2 JP7425066 B2 JP 7425066B2
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- sort
- cationic
- composition
- cas9
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Optics & Photonics (AREA)
- Manufacturing & Machinery (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023189771A JP7815196B2 (ja) | 2018-09-04 | 2023-11-07 | 核酸を臓器特異的送達するための組成物および方法 |
| JP2026016550A JP2026082961A (ja) | 2018-09-04 | 2026-02-04 | 核酸を臓器特異的送達するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862726741P | 2018-09-04 | 2018-09-04 | |
| US62/726,741 | 2018-09-04 | ||
| PCT/US2019/049565 WO2020051223A1 (en) | 2018-09-04 | 2019-09-04 | Compositions and methods for organ specific delivery of nucleic acids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023189771A Division JP7815196B2 (ja) | 2018-09-04 | 2023-11-07 | 核酸を臓器特異的送達するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021535227A JP2021535227A (ja) | 2021-12-16 |
| JP2021535227A5 JP2021535227A5 (cg-RX-API-DMAC7.html) | 2022-09-13 |
| JP7425066B2 true JP7425066B2 (ja) | 2024-01-30 |
Family
ID=69722750
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536681A Active JP7425066B2 (ja) | 2018-09-04 | 2019-09-04 | 核酸を臓器特異的送達するための組成物および方法 |
| JP2023189771A Active JP7815196B2 (ja) | 2018-09-04 | 2023-11-07 | 核酸を臓器特異的送達するための組成物および方法 |
| JP2026016550A Pending JP2026082961A (ja) | 2018-09-04 | 2026-02-04 | 核酸を臓器特異的送達するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023189771A Active JP7815196B2 (ja) | 2018-09-04 | 2023-11-07 | 核酸を臓器特異的送達するための組成物および方法 |
| JP2026016550A Pending JP2026082961A (ja) | 2018-09-04 | 2026-02-04 | 核酸を臓器特異的送達するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (9) | US11229609B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3846822A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7425066B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN120093931A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019336679B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3111484A1 (cg-RX-API-DMAC7.html) |
| GB (3) | GB2606038B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020051223A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108368028B (zh) | 2015-10-28 | 2021-09-03 | 爱康泰生治疗公司 | 用于递送核酸的新型脂质和脂质纳米颗粒制剂 |
| US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
| US12678515B2 (en) | 2015-12-30 | 2026-07-14 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| CA3025626A1 (en) | 2016-05-27 | 2017-11-30 | Transcriptx, Inc. | Treatment of primary ciliary dyskinesia with synthetic messenger rna |
| KR20190064600A (ko) | 2016-09-23 | 2019-06-10 | 듀크 유니버시티 | Lcst 거동을 갖는 비구조화된 비-반복적 폴리펩티드 |
| EP3658168A4 (en) | 2017-06-30 | 2021-07-14 | Duke University | ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-RESPONDING BIOPOLYMER NETWORKS |
| WO2019045897A1 (en) * | 2017-08-31 | 2019-03-07 | Life Technologies Corporation | CATIONIC LIPIDIC COMPOSITIONS FOR TISSUE-SPECIFIC ADMINISTRATION |
| WO2019147954A1 (en) | 2018-01-26 | 2019-08-01 | Duke University | Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same |
| WO2019213150A1 (en) | 2018-04-30 | 2019-11-07 | Duke University | Stimuli-responsive peg-like polymer-based drug delivery platform |
| US12357580B2 (en) | 2018-06-19 | 2025-07-15 | The Board Of Regents Of The University Of Texas System | Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids |
| GB2606038B (en) | 2018-09-04 | 2023-05-03 | Univ Texas | Compositions and methods for organ specific delivery of nucleic acids |
| GB2600800B (en) | 2018-09-04 | 2023-08-16 | Univ Texas | Compositions and methods for organ specific delivery of nucleic acids |
| WO2020051541A1 (en) | 2018-09-07 | 2020-03-12 | Duke University | Nanoparticulate drug delivery systems |
| US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
| KR20220044816A (ko) * | 2019-08-12 | 2022-04-11 | 인티그레이티드 나노테라퓨틱스 아이엔씨. | 하전 물질 전달을 위한 지질, 이의 제형 및 그 제조 방법 |
| US20240293317A1 (en) * | 2020-04-20 | 2024-09-05 | Board Of Regents, The University Of Texas System | Lipid nanoparticle (lnp) delivery systems and uses thereof |
| EP4153560A4 (en) * | 2020-05-19 | 2024-04-24 | Ramot at Tel-Aviv University Ltd. | LIPID PARTICLES FOR NUCLEIC ACID DELIVERY AND CLINICAL APPLICATIONS THEREOF |
| MX2023004371A (es) | 2020-10-14 | 2023-07-26 | George Mason Res Foundation Inc | Lípidos ionizables, y métodos de fabricación y uso de los mismos. |
| JP2024500879A (ja) * | 2020-12-22 | 2024-01-10 | コーネル ユニヴァーシティー | 双性イオン性脂質ナノ粒子組成物およびその使用方法 |
| MX2023011227A (es) * | 2021-03-22 | 2023-12-06 | Recode Therapeutics Inc | Composiciones y metodos para administracion dirigida a celulas. |
| WO2022204043A1 (en) * | 2021-03-22 | 2022-09-29 | The Board Of Regents Of The University Of Texas System | Compositions and methods for targeted delivery to cells |
| IL305958A (en) * | 2021-03-22 | 2023-11-01 | Recode Therapeutics Inc | Polynucleotide preparations, related formulations and methods of using them |
| MX2023011243A (es) | 2021-03-23 | 2023-12-14 | Recode Therapeutics Inc | Composiciones de polinucleotidos, formulaciones relacionadas y metodos de uso de los mismos. |
| KR20240024041A (ko) * | 2021-03-23 | 2024-02-23 | 리코드 테라퓨틱스, 인크. | 세포로의 표적화 전신 전달을 위한 조성물 및 방법 |
| CN117750948A (zh) * | 2021-03-23 | 2024-03-22 | 瑞科德治疗公司 | 用于靶向全身性递送至细胞的组合物和方法 |
| JP2024516164A (ja) * | 2021-04-22 | 2024-04-12 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 正確なインビボhdr介在性遺伝子編集を可能にするオールインワンデンドリマーベース脂質ナノ粒子 |
| KR20240027630A (ko) * | 2021-06-01 | 2024-03-04 | 나노베이션 테라퓨틱스 인크. | 지질 나노입자를 사용한 dna 벡터 전달 |
| EP4422605A4 (en) * | 2021-10-25 | 2025-06-18 | Duke University | Poegma-based lipid nanoparticles |
| US20260151350A1 (en) * | 2021-12-27 | 2026-06-04 | The Board Of Regents Of The University Of Texas System | Compositions and methods for targeted delivery to cells |
| WO2023158738A2 (en) * | 2022-02-16 | 2023-08-24 | Trustees Of Tufts College | Lipid nanoparticles for delivery to the eye or ear |
| WO2023165583A1 (zh) * | 2022-03-04 | 2023-09-07 | 益杰立科(上海)生物科技有限公司 | 靶向眼部细胞的递送系统和方法 |
| KR20240157096A (ko) | 2022-03-23 | 2024-10-31 | 나노베이션 테라퓨틱스 인크. | 고 스테롤-함유 지질 나노입자 |
| WO2023192503A1 (en) * | 2022-03-30 | 2023-10-05 | The Johns Hopkins University | Compositions of lipid nanoparticles for plasmid dna delivery to the liver and methods for preparing the same |
| US12011507B2 (en) * | 2022-04-01 | 2024-06-18 | Nanovation Therapeutics Inc. | MRNA delivery composition |
| WO2023218420A1 (en) | 2022-05-13 | 2023-11-16 | Janssen Pharmaceuticals, Inc. | Mrna compositions for inducing latent hiv-1 reversal |
| CN114887070B (zh) * | 2022-06-06 | 2023-09-22 | 郑州大学第一附属医院 | 一种脾脏靶向的纳米药物 |
| CN114887071B (zh) * | 2022-06-06 | 2023-09-22 | 郑州大学第一附属医院 | 一种靶向脾脏的纳米递送载体 |
| CN114891808B (zh) * | 2022-06-21 | 2023-10-27 | 珠海丽凡达生物技术有限公司 | 编码ALDH2多肽的mRNA分子、应用及mRNA药物 |
| WO2024006960A1 (en) * | 2022-06-29 | 2024-01-04 | Juno Therapeutics, Inc. | Lipid nanoparticles for delivery of nucleic acids |
| CN119486721A (zh) | 2022-07-08 | 2025-02-18 | 宝利普拉斯生物转染公司 | 包含基于咪唑鎓的阳离子脂质的脂质纳米颗粒 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US20250360083A1 (en) * | 2022-09-21 | 2025-11-27 | Board Of Regents Of The University Of Nebraska | Lipid nanoparticle formulations and methods of use thereof |
| CN116236565B (zh) * | 2022-11-21 | 2025-06-27 | 成都诺恩生物科技有限公司 | 适合于肌注给药的核酸-脂质纳米颗粒、制剂及其应用 |
| JP2025538636A (ja) * | 2022-11-24 | 2025-11-28 | ザミディアム セラピューティクス カンパニー リミテッド | 核酸送達のための新規脂質及び脂質ナノ粒子組成物 |
| IL321026A (en) | 2022-12-08 | 2025-07-01 | Recode Therapeutics Inc | Nanoparticle formulations and their uses |
| CN116270534B (zh) * | 2022-12-13 | 2024-11-26 | 山东大学 | 一种组织选择性递送核酸药物的类脂质纳米颗粒及其制备方法和应用 |
| EP4385523A1 (en) * | 2022-12-14 | 2024-06-19 | Beijing Jitai Pharmaceutical Technology Co., Ltd. | Lipid-based topical injection formulations |
| CN116211831A (zh) * | 2022-12-14 | 2023-06-06 | 北京剂泰医药科技有限公司 | 脂质基质局部注射制剂 |
| CN121263401A (zh) | 2022-12-22 | 2026-01-02 | 内诺维什疗法股份有限公司 | 用于递送核酸和其他治疗剂的含硫的可电离脂质 |
| CN116199646B (zh) * | 2023-03-07 | 2024-01-26 | 山东大学 | 一种基于Tris的可电离脂质及其制备方法与应用 |
| EP4694867A2 (en) * | 2023-04-13 | 2026-02-18 | Massachusetts Institute of Technology | Lipid nanoparticles for delivery of agents |
| CN116271105B (zh) * | 2023-05-18 | 2023-08-25 | 上海贝斯昂科生物科技有限公司 | 一种适于rpe细胞转染的脂质纳米颗粒及其应用 |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025029927A1 (en) * | 2023-07-31 | 2025-02-06 | The Board Of Regents Of The University Of Texas System | Lipid nanoparticle |
| WO2025036297A1 (zh) | 2023-08-11 | 2025-02-20 | 浙江海昶生物医药技术有限公司 | 一种具有靶向性的脂质组合物及其制备方法 |
| US12343429B2 (en) | 2023-10-05 | 2025-07-01 | Nanovation Therapeutics Inc. | Method of delivery of DNA or RNA cargo unshielded lipid nanoparticles and compositions thereof |
| EP4788823A1 (en) * | 2023-10-05 | 2026-08-12 | Nanovation Therapeutics Inc. | Haematopoietic stem and/or progenitor cell delivery method and compositions for use thereof |
| WO2025081189A1 (en) * | 2023-10-12 | 2025-04-17 | Georgia Tech Research Corporation | Methods and compositions for lipid nanoparticle (lnp) mediated delivery of mrna encoded synthetic antigens for universal tumor targeting by car t cells |
| WO2025088597A1 (en) * | 2023-10-26 | 2025-05-01 | New Phase Ltd. | Nanoparticle combination therapy for tumors |
| WO2025108545A1 (en) * | 2023-11-22 | 2025-05-30 | Danmarks Tekniske Universitet | Delivery of nucleotides from injectable biomaterial |
| US12553042B2 (en) | 2023-12-01 | 2026-02-17 | Recode Therapeutics, Inc. | Method for quantifying an amount of capped messenger RNA |
| US12364773B2 (en) | 2023-12-01 | 2025-07-22 | Recode Therapeutics, Inc. | Lipid nanoparticle compositions and uses thereof |
| WO2025133684A1 (en) * | 2023-12-21 | 2025-06-26 | Vilnius University | Liposomal nanoparticles for crispr/cas9 delivery |
| CN120398741A (zh) * | 2024-01-29 | 2025-08-01 | 江苏中天药业有限公司 | 一种用于递送核酸物质的脂肪酸衍生物及其合成方法 |
| CN118001254B (zh) | 2024-04-09 | 2024-07-26 | 北京悦康科创医药科技股份有限公司 | 靶向抗原呈递细胞的脂质组合物及其应用 |
| WO2025213270A1 (en) * | 2024-04-11 | 2025-10-16 | Nanovation Therapeutics Inc. | Method of delivering nucleic acid to t cells and compositions for use thereof |
| WO2025226642A1 (en) * | 2024-04-25 | 2025-10-30 | Eli Lilly And Company | Lipid nano delivery particles for targeted transport of nucleic acids and methods of making and using the same |
| WO2025228975A1 (en) * | 2024-04-29 | 2025-11-06 | BioNTech SE | Particles, compositions and methods |
| WO2025228979A1 (en) | 2024-04-30 | 2025-11-06 | Neovac Ltd. | Lipids nanoparticle formulations suitable for lung targeting |
| WO2026025110A1 (en) * | 2024-07-26 | 2026-01-29 | Trevi Therapeutics, Inc. | Treatment of refractory chronic cough |
| WO2026030816A1 (en) * | 2024-08-04 | 2026-02-12 | Nanovation Therapeutics Inc. | Mrna expression method and composition thereof |
| CN118750468B (zh) * | 2024-09-05 | 2025-02-18 | 北京悦康科创医药科技股份有限公司 | 一种核酸-脂质纳米颗粒冻干组合物及其制备方法和应用 |
| KR20260043575A (ko) * | 2024-09-24 | 2026-03-31 | 주식회사 녹십자 | 선택적 장기 표적 지질을 포함하는 조성물 |
| CN121610533B (zh) * | 2026-02-03 | 2026-04-17 | 中国海洋大学三亚海洋研究院 | 用于鱼类在体皮肤基因编辑的脂质纳米颗粒及其应用 |
| CN122187682B (zh) * | 2026-05-13 | 2026-08-11 | 杭州星辰智曜生物科技有限公司 | 提高可雾化脂质纳米颗粒稳定性的永久阳离子脂质及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014523411A (ja) | 2011-06-08 | 2014-09-11 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | mRNA送達のための脂質ナノ粒子組成物および方法 |
| JP2015519346A (ja) | 2012-05-23 | 2015-07-09 | ジ・オハイオ・ステート・ユニバーシティ | アンチセンスオリゴヌクレオチドを送達するための脂質ナノ粒子組成物 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| CA2289702C (en) | 1997-05-14 | 2008-02-19 | Inex Pharmaceuticals Corp. | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| US7053150B2 (en) | 2000-12-18 | 2006-05-30 | Nektar Therapeutics Al, Corporation | Segmented polymers and their conjugates |
| US7314956B2 (en) | 2001-08-08 | 2008-01-01 | Vaxim, Inc. | Multifunctional carrier for the delivery of a pharmacological agent or genetic material into a cell |
| US8871709B2 (en) * | 2003-02-05 | 2014-10-28 | Queensland University of Technolgy | Synthetic chimeric proteins comprising epidermal growth factor and vitronectin |
| US7985424B2 (en) | 2004-04-20 | 2011-07-26 | Dendritic Nanotechnologies Inc. | Dendritic polymers with enhanced amplification and interior functionality |
| DK1771206T3 (en) | 2004-05-05 | 2018-05-22 | Silence Therapeutics Gmbh | LIPIDS, LIPID COMPLEXES AND USE THEREOF |
| CA2569664C (en) | 2004-06-07 | 2013-07-16 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| WO2006138380A2 (en) | 2005-06-15 | 2006-12-28 | Massachusetts Institute Of Technology | Amine-containing lipids and uses thereof |
| US20090221684A1 (en) | 2005-12-22 | 2009-09-03 | Trustees Of Boston University | Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof |
| EP2046266A4 (en) | 2006-07-21 | 2009-11-04 | Massachusetts Inst Technology | ENDMODICIFIED POLY (BETA AMINO ESTER) AND ITS USE |
| US20110038941A1 (en) * | 2007-12-27 | 2011-02-17 | The Ohio State University Research Foundation | Lipid Nanoparticle Compositions and Methods of Making and Using the Same |
| WO2009111088A2 (en) | 2008-01-02 | 2009-09-11 | The Johns Hopkins University | Antitumor immunization by liposomal delivery of vaccine to the spleen |
| EP2279254B1 (en) | 2008-04-15 | 2017-07-05 | Protiva Biotherapeutics Inc. | Novel lipid formulations for nucleic acid delivery |
| WO2010053572A2 (en) | 2008-11-07 | 2010-05-14 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| US8163861B2 (en) | 2009-01-15 | 2012-04-24 | Living Proof, Inc. | Beta-amino ester compounds and uses thereof |
| CA2760706C (en) | 2009-05-05 | 2019-08-06 | Alnylam Pharmaceuticals, Inc. | Methods of delivering oligonucleotides to immune cells |
| CA2763819A1 (en) | 2009-06-02 | 2010-12-09 | Nian WU | Pure peg-lipid conjugates |
| CN101591428B (zh) | 2009-06-29 | 2011-05-25 | 浙江大学 | 一种聚酯树枝状大分子的制备方法 |
| SI2506857T1 (en) | 2009-12-01 | 2018-08-31 | Translate Bio, Inc. | Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases |
| CN103153284B (zh) | 2010-07-06 | 2015-11-25 | 诺华股份有限公司 | 含有其pKa值有利于RNA递送的脂质的脂质体 |
| CA2807139A1 (en) * | 2010-07-31 | 2012-02-09 | The Scripps Research Institute | Liposome targeting compounds and related uses |
| WO2012090223A1 (en) | 2010-12-29 | 2012-07-05 | Indian Institute Of Science | Poly(ether imine) dendrimers and uses thereof |
| CN107043334B (zh) | 2011-06-08 | 2020-06-16 | 日东电工株式会社 | 用于定向药物输送和增强siRNA活性的化合物 |
| AU2012325997C1 (en) | 2011-10-18 | 2018-07-05 | Dicerna Pharmaceuticals, Inc. | Amine cationic lipids and uses thereof |
| BR112014024131A2 (pt) | 2012-03-29 | 2017-07-25 | Shire Human Genetic Therapies | lipídios catiônicos ionizáveis |
| CN104411338A (zh) * | 2012-04-02 | 2015-03-11 | 现代治疗公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
| US20160289674A1 (en) * | 2012-04-02 | 2016-10-06 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of membrane proteins |
| CN104781276A (zh) | 2012-08-14 | 2015-07-15 | 安吉奥开米公司 | 肽-树枝状聚合物结合物及其用途 |
| AU2013380825B2 (en) | 2012-10-16 | 2017-07-20 | Biomics Biotechnologies Co., Ltd. | Lipidosome preparation, preparation method and application thereof |
| JP6241193B2 (ja) | 2012-10-23 | 2017-12-06 | コニカミノルタ株式会社 | 透明電極、電子デバイス及び有機エレクトロルミネッセンス素子 |
| US20140186332A1 (en) * | 2012-12-28 | 2014-07-03 | NX Pharmagen | Biomarkers of preterm birth |
| HK1217085A1 (zh) * | 2012-12-28 | 2016-12-23 | Tarveda Therapeutics, Inc | 包封在顆粒中的靶向綴合物及其製劑 |
| KR102311614B1 (ko) * | 2013-03-14 | 2021-10-08 | 샤이어 휴먼 지네틱 테라피즈 인크. | Cftr mrna 조성물 및 관련 방법 및 사용 |
| ES2967701T3 (es) | 2013-03-15 | 2024-05-03 | Translate Bio Inc | Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas |
| ES2707966T3 (es) | 2013-10-22 | 2019-04-08 | Translate Bio Inc | Terapia de ARNm para la deficiencia en síntesis de argininosuccinato |
| CN111206032B (zh) | 2013-12-12 | 2024-07-19 | 布罗德研究所有限公司 | 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用 |
| PL3122878T3 (pl) | 2014-03-24 | 2019-06-28 | Translate Bio, Inc. | TERAPIA mRNA DO LECZENIA CHORÓB OCZU |
| WO2015154002A1 (en) | 2014-04-04 | 2015-10-08 | Ohio State Innovation Foundation | Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same |
| HRP20220070T1 (hr) | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Cjepiva nukleinske kiseline |
| WO2015191693A2 (en) * | 2014-06-10 | 2015-12-17 | Massachusetts Institute Of Technology | Method for gene editing |
| CN103999853B (zh) | 2014-06-11 | 2015-07-22 | 中国农业大学 | 荧光树枝状纳米大分子在制备药物载体中的应用 |
| CN106794141B (zh) * | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| CN107530399B (zh) | 2014-10-10 | 2022-03-18 | 马萨诸塞眼科耳科诊所 | 治疗分子在体外和体内的有效递送 |
| AU2015357562B2 (en) | 2014-12-05 | 2021-10-21 | Translate Bio, Inc. | Messenger RNA therapy for treatment of articular disease |
| AU2015360794B2 (en) | 2014-12-08 | 2021-07-08 | The Board Of Regents Of The University Of Texas System | Lipocationic polymers and uses thereof |
| EP3247328B1 (en) | 2015-01-21 | 2026-01-07 | Genevant Sciences Gmbh | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells |
| EP3247398A4 (en) * | 2015-01-23 | 2018-09-26 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| ES2898340T3 (es) * | 2015-07-09 | 2022-03-07 | Insmed Inc | Composiciones y métodos para tratar neumopatías y lesión pulmonar |
| KR102764250B1 (ko) * | 2015-09-14 | 2025-02-07 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 지질양이온성 덴드리머 및 이의 용도 |
| US20180258411A1 (en) | 2015-09-25 | 2018-09-13 | Tarveda Therapeutics, Inc. | Compositions and methods for genome editing |
| JP2018530587A (ja) * | 2015-10-16 | 2018-10-18 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | mRNAキャップ類似体およびmRNAキャッピングの方法 |
| MA46023A (fr) * | 2015-10-22 | 2019-07-03 | Modernatx Inc | Vaccin contre le virus de la grippe à large spectre |
| ES3030658T3 (en) * | 2016-03-30 | 2025-07-01 | Intellia Therapeutics Inc | Lipid nanoparticle formulations for crispr/cas components |
| EP3442590A2 (en) * | 2016-04-13 | 2019-02-20 | Modernatx, Inc. | Lipid compositions and their uses for intratumoral polynucleotide delivery |
| PL3458074T3 (pl) | 2016-05-16 | 2024-11-12 | Board Of Regents Of The University Of Texas System | KOMPOZYCJA DO DOSTARCZANIA tRNA W POSTACI NANOCZĄSTEK I SPOSOBY ICH STOSOWANIA |
| PL3458083T3 (pl) * | 2016-05-18 | 2023-03-13 | Modernatx, Inc. | Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania |
| CN109562153A (zh) * | 2016-08-07 | 2019-04-02 | 诺华股份有限公司 | mRNA介导的免疫方法 |
| KR20190093816A (ko) * | 2016-10-26 | 2019-08-26 | 큐어백 아게 | 지질 나노입자 mRNA 백신 |
| EP3315125A1 (en) * | 2016-10-31 | 2018-05-02 | Silence Therapeutics (London) Ltd | Lipid nanoparticle formulation |
| GB2596224B (en) * | 2018-06-19 | 2022-09-07 | Univ Texas | Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids |
| GB2606038B (en) | 2018-09-04 | 2023-05-03 | Univ Texas | Compositions and methods for organ specific delivery of nucleic acids |
| GB2600800B (en) | 2018-09-04 | 2023-08-16 | Univ Texas | Compositions and methods for organ specific delivery of nucleic acids |
-
2019
- 2019-09-04 GB GB2111271.9A patent/GB2606038B/en active Active
- 2019-09-04 EP EP19857774.4A patent/EP3846822A4/en active Pending
- 2019-09-04 CA CA3111484A patent/CA3111484A1/en active Pending
- 2019-09-04 WO PCT/US2019/049565 patent/WO2020051223A1/en not_active Ceased
- 2019-09-04 CN CN202510183613.1A patent/CN120093931A/zh active Pending
- 2019-09-04 GB GB2219703.2A patent/GB2617430B/en active Active
- 2019-09-04 GB GB2104777.4A patent/GB2592505B/en active Active
- 2019-09-04 CN CN201980070622.2A patent/CN112996519B/zh active Active
- 2019-09-04 AU AU2019336679A patent/AU2019336679B2/en active Active
- 2019-09-04 JP JP2021536681A patent/JP7425066B2/ja active Active
-
2021
- 2021-03-04 US US17/191,895 patent/US11229609B2/en active Active
- 2021-09-13 US US17/473,863 patent/US11304911B2/en active Active
-
2022
- 2022-01-10 US US17/572,615 patent/US11590085B2/en active Active
- 2022-04-01 US US17/711,911 patent/US11510880B2/en active Active
- 2022-06-14 US US17/839,699 patent/US11648209B2/en active Active
- 2022-09-04 US US17/929,704 patent/US11648210B2/en active Active
-
2023
- 2023-11-07 JP JP2023189771A patent/JP7815196B2/ja active Active
- 2023-12-11 US US18/534,974 patent/US12133924B2/en active Active
-
2024
- 2024-02-28 US US18/590,737 patent/US20240245620A1/en not_active Abandoned
-
2025
- 2025-01-16 US US19/025,939 patent/US20250228788A1/en not_active Abandoned
- 2025-08-29 AU AU2025223878A patent/AU2025223878A1/en active Pending
-
2026
- 2026-02-04 JP JP2026016550A patent/JP2026082961A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014523411A (ja) | 2011-06-08 | 2014-09-11 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | mRNA送達のための脂質ナノ粒子組成物および方法 |
| JP2015519346A (ja) | 2012-05-23 | 2015-07-09 | ジ・オハイオ・ステート・ユニバーシティ | アンチセンスオリゴヌクレオチドを送達するための脂質ナノ粒子組成物 |
| JP2015525209A (ja) | 2012-05-23 | 2015-09-03 | ジ・オハイオ・ステート・ユニバーシティ | 脂質ナノ粒子組成物と、それを作製する方法、及びそれを使用する方法 |
Non-Patent Citations (1)
| Title |
|---|
| Advanced Materials,2017年,Vol.29, No.33,Article ID 1606944, p.1-7 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7815196B2 (ja) | 核酸を臓器特異的送達するための組成物および方法 | |
| US11766408B2 (en) | Compositions and methods for organ specific delivery of nucleic acids | |
| AU2022244355A1 (en) | Compositions and methods for targeted systemic delivery to cells | |
| HK40055120B (en) | Compositions and methods for organ specific delivery of nucleic acids | |
| HK40055120A (en) | Compositions and methods for organ specific delivery of nucleic acids | |
| HK40055907A (en) | Compositions and methods for organ specific delivery of nucleic acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220905 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220905 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20220905 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221109 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230207 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230509 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230710 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231107 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231115 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20231205 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231227 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240118 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7425066 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |